Favourable effect of TNF‐α inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novoCARD15 mutation
Abstract
Blau syndrome is a hereditary granulomatous disease caused by mutations in the CARD15 gene that is diagnosed in children of young age with exanthema/erythema, arthritis/periarthritis and/or uveitis. We report two cases of Blau syndrome in Danish Caucasian monozygotic male twins, exhibiting a heterozygous de novo R334W mutation in codon 334 of CARD15. The patients were initially diagnosed as having sarcoidosis. In both twins, symptoms (exanthema, arthritis/periarthritis) started at 1 year of age, and were followed by uveitis at 7–10 years of age. There was no involvement of the lungs or other organs. An initial course of standard antituberculous treatment had no effect on the symptoms. Hydroxychloroquine and cyclosporine A were also ineffective, and the latter caused impaired renal function. Partial symptomatic relief was obtained with prednisolone and increased benefit was observed in combination with methotrexate. Subsequent introduction of the TNF‐α inhibitor eternacept did not discernibly benefit the clinical condition, but was associated with recurrent infections. In contrast, a trial of infliximab therapy demonstrated clinical efficacy and eliminated all symptoms, restoring a high quality of life. At follow up at 20 years of age (after 2–5 years of infliximab treatment) the twins had an almost normal physical appearance and a normal psychomotoric development, indicating a favourable short‐term prognosis of the disease. Blau syndrome has pathologic, clinical and therapeutic features in common with sarcoidosis, but rarely involves the lungs or other parenchymatous organs. In children, discrimination between early onset sarcoidosis and Blau syndrome should include a CARD15 mutation analysis.Keywords
This publication has 22 references indexed in Scilit:
- Blau syndrome and related genetic disorders causing childhood arthritisCurrent Rheumatology Reports, 2005
- Routine Hospital Use of a New Commercial Whole Blood Interferon-γ Assay for the Diagnosis of Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2005
- A new CARD15 mutation in Blau syndromeEuropean Journal of Human Genetics, 2005
- Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor- B activation: common genetic etiology with Blau syndromeBlood, 2004
- CARD15 gene mutations in sarcoidosisEuropean Respiratory Journal, 2003
- CARD15/NOD2 Mutational Analysis and Genotype-Phenotype Correlation in 612 Patients with Inflammatory Bowel DiseaseThe American Journal of Human Genetics, 2002
- CARD15 mutations in Blau syndromeNature Genetics, 2001
- Blau syndrome of granulomatous arthritis, iritis, and skin rash: A new family and review of the literatureAmerican Journal of Medical Genetics, 1998
- Autosomal dominant granulomatous arthritis, uveitis, skin rash, and synovial cystsThe Journal of Pediatrics, 1990
- Familial granulomatous arthritis, iritis, and rashThe Journal of Pediatrics, 1985